Viatris Inc.
Viatris Inc. (VTRS) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
vtrs · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Viatris Inc. (VTRS) measures how much investors pay for each dollar of the company's trailing earnings. VTRS's current PE ratio of N/A is calculated by dividing its stock price of $15.93 by its TTM earnings per share of -$0.26.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 14 fiscal years · Front-end computedMinQ1 · 25%28.3x
MedianQ3 · 75%670.0x
Max
At N/A, VTRS's current P/E is lower than in 0% of its annual fiscal year readings over the past 14 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Viatris Inc.You VTRS | $18.6B | N/A | — | -$0.26 |
 Baxter International Inc. BAX | $9.9B | N/A | — | -$1.87 |
 BridgeBio Pharma, Inc. BBIO | $13.2B | N/A | — | -$3.70 |
 Elanco Animal Health Incorporated ELAN | $11.8B | N/A | — | -$0.47 |
 Exact Sciences Corporation EXAS | $20.0B | N/A | — | -$1.10 |
 Ionis Pharmaceuticals, Inc. IONS | $12.2B | N/A | — | -$2.38 |
 Moderna, Inc. MRNA | $18.9B | N/A | — | -$7.25 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-3.00 | — | |
2024-12-31 FY2024 | — | $-0.53 | — | |
2023-12-31 FY2023 | 237.65x | $0.05 | +3561.6% | |
2022-12-31 FY2022 | 6.49x | $1.71 | — | |
2021-12-31 FY2021 | — | $-1.05 | — | |
2020-12-31 FY2020 | — | $-1.11 | — | |
2019-12-31 FY2019 | 670.00x | $0.03 | +1568.8% | |
2018-12-30 FY2018 | 40.15x | $0.68 | +23.4% | |
2017-12-30 FY2017 | 32.55x | $1.30 | -21.3% | |
2016-12-30 FY2016 | 41.37x | $0.92 | +30.4% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Viatris Inc. (VTRS) measures how much investors pay for each dollar of the company's trailing earnings. VTRS's current PE ratio of N/A is calculated by dividing its stock price of $15.93 by its TTM earnings per share of -$0.26.
Frequently asked questions
VTRS pe ratio · 6 questionsVTRS's current PE ratio is N/A as of 2026-06-08, based on a stock price of $15.93 and TTM EPS of -$0.26. Data sourced from Financial Modeling Prep via VTRS's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Viatris Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08